1. Observations on the administration of autologous lymphokineactivated killer cells and recombinant Interleukin-2 to patients with metastatic cancer;Rosenberg, S.A.; Lotze, M.T.; Muul, L.M.;N EnglJ Med,1985
2. Treatment for unresectable hepatoma via selective hepatic arterial infusion of lymphokineactivated killer cells generated from autologous spleen cells;Ohuno, K.; Takagi, H.; Nakamura, T.; Nakamura, Y.; Iwasa, Z.; Yasutomi, M.;Cancer,1986
3. Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant Interleukin 2;Lafreniere, R.; Rosenberg, S.A.;C'ancer Res,1985
4. Antitumour efficacy of lymphokine-activated killer cells and recombinant. Interleukin-2 in vivo: Survival benefit and mechanisms of tumour escape in mice undergoing immunotherapy;Mule, J.J.; Ettinghausen, S.E.; Spiess, P.J.; Shu, S.; Rosenberg, S.A.;Cancer Res,1986
5. Lymphokine activated tumour inhibition in vivo 1. The local administration of Interleukin-2 triggers nonreactive lymphocytes from tumour-bearing mice to inhibit tumour growth;Forni, G.; Giovarelli, M.; Santoni, A.;J Immunol,1985